First Patient Enrolled in Phase I MagSense® HER2+ Breast Cancer Study

First Patient Enrolled in Phase I MagSense® HER2+ Breast Cancer Study

This week Imagion Biosystems has announced we have enrolled our first patient into our first clinical study.

This is an important step for our Phase I MagSense® HER2 breast cancer study. The study investigates the use of a MagSense® imaging agent as a means of aiding in the staging of HER2 positive breast cancer by detecting if the patient’s tumor has spread to the lymph nodes.

Read the full announcement here.

Related Articles

Successful Placement of A$3M

Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.